Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of JWK001 in neovascular age-related macular degeneration
CTR20241792Phase 2Active
- Sponsor
- Chengdu Genevector Biotechnology Co. Ltd.
- Start
- Jul 2024
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of JWK001 in exudative macular degeneration, sponsored by Chengdu Genevector Biotechnology Co. Ltd.. Started Jul 2024; status: active.
02
Drugs
JWK001
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20241792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241792.